Overview
Lessons Learned and New Opportunities: Strategies for Meaningful and Sustainable Improvements to Reduce Health Disparities in Prostate Cancer
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Are you aware that Black men continue to suffer worse outcomes compared to White men with prostate cancer? This digital interactive tool provides clinicians with expert insight videos that offer perspective on these disparities and what healthcare providers can do to address them. Through this education, learners improve their ability to recognize systemic, behavioral and sociocultural factors creating disparate health outcomes in prostate cancer, improve identification of patients at risk, and expedite time to diagnosis and time to treatment.
This activity is intended for oncologists, urologists, primary care physicians, and specialty advance practice providers.
This interactive tool is interspersed with videos of leading experts in prostate cancer disparities research. The materials and resources provided in this activity help learners become better able to identify systemic, behavioral, and sociocultural variables that continue to contribute to prostate cancer inequities. The experts in this activity provide insights and resources for learners to help address these disparities not only on patient level, but also within their own institution.
Upon completion of this activity, participants will be able to:
• Outline the latest research relating to prostate cancer disparities of care
• Review the importance of biomarker testing in African American patients to improve risk stratification and optimize treatment strategies
• Apply latest clinical data on active surveillance, definitive therapies and systemic therapies to personalize management of African American men with various grades of prostate cancer
• Apply tactics to improve care coordination, access to care and SDM for African American prostate cancer patients
• Outline the latest research relating to prostate cancer disparities of care
• Review the importance of biomarker testing in African American patients to improve risk stratification and optimize treatment strategies
• Apply latest clinical data on active surveillance, definitive therapies and systemic therapies to personalize management of African American men with various grades of prostate cancer
• Apply tactics to improve care coordination, access to care and SDM for African American prostate cancer patients
Sponsored by Rush University Medical Center, in partnership with the Academy for Continued Healthcare Learning (ACHL).
Supported by educational grants from Astellas and Pfizer, Inc., and Bayer HealthCare Pharmaceuticals Inc.
Brian Keith McNeil, MD, MBA
Associate Dean for Clinical Affairs
Vice-Chair, Department of Urology
SUNY Downstate Health Sciences University
Brooklyn, NY
Associate Dean for Clinical Affairs
Vice-Chair, Department of Urology
SUNY Downstate Health Sciences University
Brooklyn, NY
Kelvin A. Moses, MD, PhD
Associate Professor
Vanderbilt University Medical Center
Nashville, TN
As a provider of continuing education, Rush University Medical Center asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education. Mechanisms are in place to identify and mitigate any potential conflict of interest prior to the start of the activity. All information disclosed must be shared with the participants/learners prior to the start of the educational activity.
The below faculty do not have any relevant financial relationships with ineligible companies to disclose:
Brian Keith McNeil, MD, MBA, FACS
Kelvin A. Moses, MD, PhD, FACS
Unapproved Uses of Drugs/Devices: Not applicable
ACHL and Rush University Medical Center staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships with ineligible companies to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME and ACPE Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduing material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
